Hybrid-Rx

Hybrid-Rx is a biotechnology company developing a novel class of therapeutics based on its proprietary Hybrid RNA (hRNA) platform. The company's technology combines the strengths of different RNA modalities to create synthetic molecules with enhanced stability, targeting, and therapeutic efficacy. Founded by pioneers in RNA biology and drug development, Hybrid-Rx is initially focusing on oncology indications where its hRNA approach can modulate disease-driving pathways that are difficult to target with conventional methods. The company is currently in the pre-clinical stage, advancing a pipeline of candidates designed to address high unmet medical needs in cancer treatment. By leveraging the unique properties of hybrid RNA, Hybrid-Rx aims to overcome the delivery and stability challenges that have historically limited the potential of RNA-based medicines.